Patrick M. Woster Ph.D.

  Patrick M. Woster is Professor of Medicinal Chemistry at the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University. He received a B.S. in Pharmacy from the University of Nebraska Medical Center in 1978, and a Ph.D. in Medicinal Chemistry from the University of Nebraska - Lincoln in 1986. Following postdoctoral work in chemistry at Rensselaer Polytechnic Institute, and in medicinal chemistry at the University of Michigan, he joined the WSU Faculty in 1988. Professor Woster teaches undergraduate biochemistry and medicinal chemistry courses, graduate level courses in medicinal and bioorganic chemistry, and has developed a series of WWW-based tutorials for students in medicinal chemistry. He has been voted Teacher of the Year eight times, and received the WSU President's Award for Excellence in Teaching in 1993. He was also awarded a Wayne State University Career Development Chair in 1997.

    Professor Woster maintains an active research program that has been funded by several agencies, including the National Institutes of Health, the World Health Association and the pharmaceutical industry. Ongoing projects in the Woster laboratories include the synthesis of alkylpolyamines as antitumor or antiparasitic agents, synthesis of novel inhibitors of lysine-specific demethylase 1 and histone deacetylase as epigenetic modulators, solution- and solid-phase synthesis of peptide-based inhibitors of plasmepsin, synthesis of S-adenosylmethionine analogues as mechanism-based enzyme inhibitors and synthesis of furanocoumarins as inhibitors of cytochrome P450. Dr. Woster has directed a number of Ph.D. dissertations and Master's theses, and has mentored seven postdoctoral associates. To date, he has authored more than 75 articles in peer-reviewed research journals, and more than 100 research abstracts and invited presentations. Dr. Woster has also served as a member of two NIH study sections, and on editorial boards or as a reviewer for numerous scientific journals.

    Professor Woster has been a member of ACS and the Division of Medicinal Chemistry since 1979, and is also a member of the Organic Chemistry and Biological Chemistry divisions. He assumed an active service role in the Division of Medicinal Chemistry in 1994 as a member of the Membership Committee and Chair of the Electronic Communications Committee. Dr. Woster was a member of the Division Long Range Planning Committee (1998 - 2000), and organized 4 symposia for National ACS meetings. He has served as Secretary and Public Relations Chair for the Division of Medicinal Chemistry since 1998.  Dr. Woster has served as an officer for the American Association of Colleges of Pharmacy (AACP), where he is a Past Chair of the Section of Teachers of Chemistry. During 2004-2005, he was a member of the AACP Executive Board of Directors, and Chair of the Academic Sections Coordinating Committee.

B.S. Pharmacy 1978, University of Nebraska Medical Center
Ph.D. Medicinal Chemistry 1986, University of Nebraska - Lincoln

Univ. Nebraska Med. Ctr., Omaha, NE B.S. 1978 Pharmacy
University of Nebraska,  Lincoln NE Ph.D. 1986 Medicinal Chemistry
Rensselaer Polytechnic Inst., Troy, NY Postdoctoral Associate 1986 Chemistry
University of Michigan, Ann Arbor Postdoctoral Associate 1987 Medicinal Chemistry

Postdoctoral Associate (Jan. 1986 to Dec. 1986) - Department of Chemistry, Rensselaer Polytechnic Institute, Troy, NY 12180, under the supervision of Prof. James K. Coward.

Postdoctoral Associate (Jan. 1987 to Dec. 1987) - Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, under the supervision of Prof. James K. Coward.

Lecturer (Jan. 1988 to June 1989) - Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202.

Assistant Professor (July 1989 to August, 1995) - Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202.

Associate Professor (September, 1995 to August, 2001) - Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202.

Professor (August, 2001 - present) - Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202

Professional Societies:

Faculty Advisor, Alpha Chi Chapter of the Rho Chi Society, Wayne State University, 1995 to 1998.
Member, American Chemical Society.
ACS Division of Medicinal Chemistry:
    Appointed to Division of Medicinal Chemistry Membership Committee, March 30, 1994.
    Appointed to Division of Medicinal Chemistry Electronic Media Committee, August 20, 1994.
    Member, Long Range Planning Committee, 1998 - 2000.
    Division Secretary and Public Relations Chair, 2000 to present.
Member, ACS Division of Organic Chemistry.
Member, ACS Division of Biological Chemistry.
Member, American Association of Colleges of Pharmacy.
    Appointed to Joint Council of Deans/Council of Faculties Committee on Eliminating the Barriers to the
    Development and Implementation of Effective Teaching, December, 1994.
    Chemistry Section Communications Committee, 1995 to present (Chair, 1995-1996).
    Appointed to the Chemistry Section Ad Hoc Pharm.D./Ph.D. Committee 1996-97
    Secretary, Section of Teachers of Chemistry, 2000-2002.
    Member, AACP Academic Affairs Committee, 2000-2001
    Chair-Elect, Section of Teachers of Chemistry, 2002-2003
    Chair, Section of Teachers of Chemistry, 2003-2004
    Member, 2003-04 AACP Academic Sections Coordinating Committee
    Chair, 2004-05 AACP Academic Sections Coordinating Committee
    Member, 2004-05 AACP Board of Directors
Member, American Association for the Advancement of Science

Scientific Review Panels:

Reviewer, National Science Foundation, Division of Metabolic Biochemistry, 1996.
External Evaluator, doctoral dissertation of Laurence Covassin, Ph.D., University of Laval, Quebec
City, Quebec, August, 2000.
Expert Panel Member, Novartis Foundation Discussion Meeting, “Drugs for Developing World
Diseases: Translating New Molecular Targets into Candidates for Development”, November 3, 2003, London, UK.
Reviewer, Philip Morris External Research Grant Program, 2003.
Member, National Institutes of Health, NIAID Tropical Disease Research Unit Special Emphasis Grant
Review Panel, December 15-17, 2003, in Bethesda, MD.
Member, National Institutes of Health, NCI Program Project Grant  Review Panel, October 24-27,
2004, in Bethesda, MD.
Member, National Institutes of Health, Rapid Access to Intervention Development (RAID) Review
Panel, October, 2005.
Member, National Institutes of Health, Rapid Access to Intervention Development (RAID) Review
Panel, October, 2006.
Member, Scientific Advisory Committee, 18th International Symposium on Medicinal
Chemistry, held August 15-19, 2004, in Copenhagen, Denmark.
Reviewer, American Chemical Society, Petroleum Research Fund Grant Program, 1994 - 2005.
Member, Scientific Advisory Committee, 19th International Symposium on Medicinal Chemistry,
held September 2-6, 2006, in Istanbul, Turkey.
Member, Canadian Institutes for Health Research Drug Development Initiative Grant Review Panel,
January 11-12, 2006, in Ottawa, Ontario, CANADA.
Member, Canadian Institutes for Health Research Drug Development Initiative Grant Review Panel,
January 10-11, 2007, in Ottawa, Ontario, CANADA.

Professional Journal Affiliations:

Associate Editor, Current Medicinal Chemistry, 1998 - 2003
Editorial Board, Current Topics in Medicinal Chemistry , 2000 - 2003
Editorial Board, Mini Reviews in Medicinal Chemistry , 2000 - 2003.
Editorial Board, Current Medicinal Chemistry - Anticancer Agents, 2000 - 2003.
Editorial Board, American Journal of Pharmaceutical Education, 2003-2007.
Pharmaceutical Chemistry Board of Expert Analysts, ChemTracts Organic Chemistry, 1997 - 2002.
Reviewer, American Journal of Pharmacy Education, 1989, 1991, 1993, 1997, 1998, 2000, 2003 - 2005.
Reviewer, Bioorganic and Medicinal Chemistry Letters, 1991 to present.
Reviewer, Bioorganic and Medicinal Chemistry, 1995 to present.
Reviewer, Cellular and Molecular Biology, 1998 to present.
Reviewer, Journal of Medicinal Chemistry, 1992 to present.
Reviewer, Medicinal Chemistry Research, 2007 to present.
Reviewer, Journal of Organic Chemistry, 2003 to present.
Reviewer, Journal of the American Chemical Society, 2004 to present.
Reviewer, Biochemical Pharmacology, 1999 to present.
Reviewer, Antimicrobial Agents and Chemotherapy, 2001 to present.
Reviewer, Organic Letters, 2001 to present.
Reviewer, Tetrahedron Letters, 2004 to present.
Reviewer, Synthesis, 2005 to present.
Reviewer, Canadian Journal of Chemistry, 2005 to present.
Reviewer, Mendeleev Communications (Russian Academy of Sciences), 2005 to present.
Reviewer, Journal of the Brazilian Society of Chemistry, 2005 to present.
Reviewer, European Journal of Medicinal Chemistry, 2005 to present.
Reviewer, Life Sciences, 2005 to present.
Reviewer, European Journal of Pharmaceutical Sciences, 2006 to present.

Consulting:

Consultant, Oridigm Pharmaceutical Co., Seattle, WA, 1996 to 2000.
Consultant, S’Lil Biomedical Corporation, Madison, WI, 2001 - 2004.
Consultant, Cellgate, Inc., Redwood City, CA, October, 2006 to present.
Expert Witness, United States v. Moccia, Boston, MA, May, 2001.
Expert Witness, United States v. Ivanov, Boston, MA, March, 2002.
Expert Witness, TASA Group, January, 2005 to present

Member, Rho Chi Pharmaceutical Honor Society
Member, Sigma Xi Research Honor Society
Member, Golden Key Honor Society

Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1988.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1989.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1990.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1991.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1992
Wayne State University President's Award for Excellence in Teaching, 1993.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1994.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1996.
Teacher of the Year, Wayne State University College of Pharmacy and Health Sciences, 1997.
Eugene Applebaum College of Pharmacy and Health Sciences Teaching Excellence Award, 1998
Eugene Applebaum College of Pharmacy and Health Sciences Teaching Excellence Award, 2006
American Men and Women of Science, 1992-2007.
Recipient, Wayne State University Career Development Chair, 1998-99
Elected Vice-Chair, 2007 Gordon Research Conference on Polyamines
Elected Chair, 2009 Gordon Research Conference on Polyamines

35. Woster, P.M.: Sleeping Sickness: Irreversible Inhibitors of S-Adenosylmethionine Decarboxylase as Antitrypanosomal Agents. In “Biomedical Chemistry”, Paul Torrence, ed., Wiley and Sons, New York, 2000, pp. 1-39.
36. Nairn, L.M.; Lindsay, G.S.; Woster, P.M.; Wallace, H.M.: Cytotoxicity of Novel Unsymmetrically-Substituted Inhibitors of Polyamine Biosynthesis in Human Cancer Cells. J. Cell. Phys. 2000, 182, 209-213.
37. McClosky, D.E.; Woster, P.M.; Casero, R.A.; Davidson, N.E.: Effects of the polyamine analogues CPENSpm and CHENSpm in human prostate cancer cells. Clin. Cancer Res. 2000, 6, 17-23.
38. Iyer, R.; Wu, Z.; Woster, P.M.; Delcour, A.H.: Molecular Basis for the Polyamine - OmpF Porin Interactions: Inhibitor and Mutant Studies. J. Molec. Biol. 2000, 297, 933-45.
39. Reilly, T.P.; Lash, L.H.; Doll, M.A.; Hein, D.W.; Woster, P.M.; Svensson, C.K.: A Role for Bioactivation and Covalent Binding Within Epidermal Keratinocytes in Sulfonamide-Induced Cutaneous Drug Reactions. J Invest Dermatol. 2000, 114, 1164-73.
40. Casero, Jr., R.A.; Woster, P.M.: Perspective: Alkylpolyamine Analogues as Chemotherapeutic Agents, J. Med. Chem, 2001, 44, 1-26.
41. Hahm, H.A., Dunn, V.R., Butash, K.A., Deveraux, W.L., Woster, P.M., Casero, R.A., Jr., and Davidson, N.E. Combination of Standard Cytotoxic Agents With Polyamine Analogs in the Treatment of Breast Cancer Cell Lines. Clinical Cancer Res. 2001, 7, 391-399.
42. Woster, P.M. New Therapies for Parasitic Infections. Ann. Rep. Med. Chem., 2001, 36, 99-108
43. Zou, Y., Wu, Z.Q., Sirisoma, N., Casero, R.A., Weiss, L.M., Lane, S., Bacchi, C.J. and Woster, P.M. Novel Alkylpolyamine Analogues That Possess Both Antiparasitic and Antimicrosporidial Activity. Bioorg. Med. Chem. Lett. 2001, 11, 1613-1617.
44. Wang, Y., Devereux, W., Woster, P.M., and Casero, R.A., Jr.: The Cloning and Characterization of the Mouse Polyamine Modulated Factor-1 (mPMF-1) Gene: An Alternatively Spliced Homologue of the Human Transcription Factor. Biochem. J. 2001, 359, 387-392.
45. Lawson, K.R.; Marek, S.; Woster, P.M.; Casero, R.A.; Gerner, E.W.: Detoxification of the Polyamine Analogue CHENSpm by Polyamine Oxidase. Clin Cancer Res 2002, 5, 1241-1247.
46. Carlisle, D.L.; Devereux, W.L.; Hacker, A.; Woster, P.M.; Casero, R.A.:Growth status significantly affects the response of human lung cancer cells to antitumor polyamine analogue exposure.Clin. Cancer Res. 2002, 8, 2684-2689.
47. Fraser AV, Woster PM, Wallace HM: Induction of apoptosis in human leukaemic cells by IPENSpm, a novel polyamine analogue and anti-metabolite. Biochem. J. 2002, 367, 307-312.
48. Casero, R.A.; Wang, Y.; Murray-Stewart, T.; Devereaux, W.; Hacker, A.; Smith, R.; Woster, P.M.: Properties of purified human polyamine oxidase PAOh1/SMO. Bioch. Soc. Trans. 2003, 31(Part 2), 361-365.

49. Casero, Jr., R.A.; Wang, Y.; Stewart, T.M.; Devereux, W.; Hacker, A.; Smith, R.; Woster, P.M.: The role of polyamine catabolism in antitumor drug response. Biochem. Soc. Trans. 2003, 31 (Part2), 605-611.
50. Wang, Y.; Murray-Stewart, T.; Devereaux, W.; Hacker, A.; Friedman, B.; Woster, P.M.; Casero, R.A.: Properties of purified human polyamine oxidase PAOh1/SMO. Bioch. Bioph. Res. Comm. 2003, 304, 605-611.
51. Woster, P.M.: New Therapies for Malaria. Ann. Rep. Med. Chem. 2003, 38, 203-212.
52. Ndjonka, D.; Zou, Y.; Bi, X.; Woster, P.M.; Walter, R.D.; Leursen, K.: The polyamine analogue BW-1 is an inhibitor of the Onchocerca volvulus S-adenosylmethionine decarboxylase Biol. Chem. 2003, 384, 1195-1201.
53. Devereux, W.; Wang, Y.; Murray Stewart, T.; Hacker, A.; Smith, R.; Frydman, B.; Valasinas, A.L.; Reddy, V.K.; Marton, L.J.; Ward, T.D.; Woster, P.M.; Casero, Jr., R.A.: Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother. Pharmacol. 2003, 52, 383–390.
54. Bacchi, C.J.; Rattendi, D.; Faciane, E.; Yarlett, N.; Weiss, L.M.; Frydman, B.; Woster, P.M.; Wei, B.; Marton, L.J.; Wittner, M.: Polyamine metabolism in the Microspora Encephalitozoon cuniculi: effects of polyamine analogues. Microbiology, 2004, 150, 1215-1224.
55. Goosen, T.C.; Cillié, D; Bailey, D.G.; Yu, C; He, K; Hollenberg, P.F.; Woster, P.M.; Cohen, L; Williams, J.A.; Rheeders, M.; Dijkstra, H.P.: Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clinical Pharmacol. Ther. 2004, 76, 607-617.
56. Wang, Y.; Hacker, A.; Murray-Stewart, T.; Fleischer, J.G.; Woster, P.M.; Casero, Jr., R.A.: Induction of human spermine oxidase SMO(PAOh1) is regulated at the levels of new mRNA synthesis, mRNA stabilization, and newly synthesized protein. Bioch. J. 2005, 386, 543-547.
57. Vyas, P.M.; Roychowdhury, S.; Woster, P.M.; Svensson, C.K.: Reactive oxygen species generation and its role in the differential cytotoxicity of the arylhydroxylamine metabolites of sulfamethoxazole and dapsone in normal human epidermal keratinocytes. Biochem. Pharmacol. 2005, 70, 275-286.
58. Wang, Y.; Hacker, A.; Murray-Stewart, T.; Frydman, B.; Woster, P.M.; Casero, Jr.,R .A.: Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): potential roles for determination of drug sensitivity. Cancer Chemother. Pharmacol., 2005, 56, 83-90.
59. Khomutov AR, Grigorenko NA, Skuridin SG, Demin AV, Vepsalaen J, Casero RA, Woster PM.: A charge-deficient analogue of spermine with chelating properties. Bioorg. Khim. 2005, 31, 303-311.
60. Huang, Y.; Pledgie, A.; Rubin, E.; Frydman, B.; Valasinas, A.L.; Reddy, V.K.; Marton, L.M.; Woster, P.M.; Casero, Jr., R.A.; Davidson, N.E.: Role of p53/p21 Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells.
Cancer Biol. Ther. 2005, 4, 1006-1014.
61. Varghese, S.; Gupta, D.; Baran, T.; Jiemjit, A.; Gore, S.D.; Casero, Jr, R.A.; Woster, P.M.: Alkyl substituted polyaminohydroxamic acids: A novel class of targeted histone deacetylase inhibitors. J. Med. Chem. 2005, 48, 6350-6365.
62. Pledgie, A.; Huang, Y.; Hacker, A.; Zhang, Z.; Woster, P.M.; Davidson, N.E.; Casero, Jr., R.A.: Spermine oxidase SMO (PAOH1), not N1-acetylpolyamine oxidase (PAO) is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. J. Biol. Chem. 2005, 280, 39843-39851.
63. Casero, Jr., R.A.; Frydman, B.; Murray-Stewart, T.M.; Woster, P.M.: Significance of targeting polyamine metabolism as an antineoplastic strategy: Unique targets for polyamine analogues. Proc. West. Pharm. Soc., 2005, 48, 24-30.
64. Khan FD, Roychowdhury S, Nemes R, Vyas PM, Woster PM, Svensson CK. Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulfamethoxazole and dapsone in normal human keratinocytes. Toxicology 2006, 218, 90-99.
65. Woster, P.M.: Polyamine structure and synthetic analogues. In “Polyamine Cell Signalling: Physiology, Pharmacology and Cancer Research”, Jian-Ying Wang and Robert A. Casero, Jr., eds., Humana Press, Totawa, New Jersey, 2006, pp 3-24.
66. Bi, X.; Lopez, C.; Bacchi, C.J.; Rattendi, D.; Woster, P.M.: Novel Alkylpolyaminoguanidines and Alkylpolyaminobiguanides with Potent Antitrypanosomal Activity. Bioorg. Med. Chem. Lett.
2006, 16, 3229-3232.
67. Woster, P.M.: Antiprotozoal agents (trypanosomiases and leishmaniases). In “Comprehensive Medicinal Chemistry – 2nd Edition”, Edited by David J Triggle and John B Taylor, Elsevier: Oxford 2006
68. Boncher, T.; Bi, X.; Varghese, S.; Casero, Jr., R.A.; Woster, P.M.: Polyamine-based analogues as biochemical probes and potential therapeutics. Bioch. Soc. Trans. 2007, 35 (Part 2), 356-363.
69. Rider, J.E.; Hacker, A.; Mackintosh, C.A.; Pegg, A.E.; Woster, P.M.; Casero, Jr., R.A.: Spermine and spermidine mediate protection against oxidative damage caused by hydrogen peroxide. Amino Acids, 2007, 33, 231-240.
70. Huang, Y.; Greene, E.; Murray-Stewart, T.; Goodwin, A.C.; Baylin, S.B.; Woster, P.M.; Casero, R.A.: Inhibition of the lysine specific demethylase, LSD1, by novel polyamine analogues results in re-expression of aberrantly silenced genes. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 8023-8028.
71. Wang, X.; Feith, D.J.; Welsh, P.; Coleman, C.S.; Lopez, C.; Woster, P.M.; O’Brien, T.G.; Pegg, A.E.: Studies of the mechanism by which increased spermidine/spermine N1-acetyltransferase activity increases susceptibility to skin carcinogenesis. Carcinogenesis 2007, 28, 2404-2411.
72. Wei, G.; DeFeo, K.; Hayes, C.S.; Woster, P.M., Mandik-Nayak, L.; Gilmour, S.K.: Elevated ornithine decarboxylase levels activate ataxia telangiectasia mutated-DNA damage signaling in normal keratinocytes. Cancer Research, 2008, 68, 2214-2222.
73. Varghese, S.; Senanayake, T.; Murray-Stewart, T.; Casero, Jr., R.A.; Woster, P.M.: Polyaminohydroxamic Acids and Polyaminobenzamides as Isoform Selective Histone Deacetylase Inhibitors. J. Med. Chem. 2008, 51, 2447-2456.
74. Susick, L.; Senanayake, T.; Veluthakal, R.; Woster, P.M.; Kowluru, A.: A novel histone deacetylase inhibitor prevents IL-1b-induced metabolic dysfunction in pancreatic b-cells. J. Cell. Molec. Med. 2008, 10, 1-38.
75. Woster, P.M.: Antiviral agents. In “Foye’s Principles of Medicinal Chemistry – 6th Edition”, Thomas Lemke and David Williams, eds., Lippincott Williams & Wilkins, Baltimore, 2009.
76. Bacchi, C.J.; Rattendi, D.; Bi, X; Woster, P.M.: Metabolism of an alkylpolyamine analog by a polyamine oxidase from the Microsporidian Encephalitozoon cuniculi. Antimicrob. Agents Chemother., 2009, 53, 2599-2604.
77. Casero, Jr., R.A.; Woster, P.M.: Perspective: Recent advances in the development of polyamine analogues as antitumor agents. J. Med. Chem. 2009,52 (15), 4551-4573.
78. Ulmari. A.; Keinanen, T.A.; Karppinen, A.; Woster, P.M.; Janne, J.; Alhonen, L.: Spermine analogsregulated expression of spermidine/spermine-N1-acetyltransferase and its effects on depletion of intracellular polyamine pools in mouse fetal fibroblasts. Biochem. J. 2009, 422, 101-109.
79. Woster, P.M.: Foreword: The ACS division of medicinal chemistry – celebrating 100 years of excellence. J. Med. Chem. 2009, ePub ahead of print, DOI: 10.1021/jm901089d.
80. Basu, H.S.; Thompson, T.A.; Church, D.; Clower, C.; Mehraein-Ghomi, F.; Amlong, C.A.; Martin, C.T.; Woster, P.M.; Lindstrom, M.J.; Wilding, G.: A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the TRAMP mouse model. Cancer Res. 2009, 69, 7689-7695.
81. Billam, M.; Hacker, A.; Pledgie, A.; Sobolewski, M.; Woster, P.M.; Zhang, Z.; Casero, Jr., R.A.; Davidson, N.E.: The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother. Pharmacol., 2009, in press.
82. Senanayake, M.D.T.; Amunugama, H.; Boncher, T.D.; Casero, Jr., R.A.; Woster, P.M.; Casero, Jr., R.A.: Design of Polyamine-Based Therapeutic Agents: New Targets and New Directions. Essays Biochem. 2009, in press.
83. Huang, Y.; Murray-Stewart, T.; Wu, Y.; Baylin, S.B.; Marton, L.J.; Woster, P.M. and Casero, Jr., R.A.: Novel oligoamine analogues inhibit lysine-specific demethylase 1 (LSD1) and induce re-expression of epigenetically silenced genes. Cancer Chemother. Pharmacol. 2009, in press.
84. Woster, P.M.: Antiprotozoal/Antiparasitic Agents. In “Burger’s Medicinal Chemistry, Drug Discovery and Development – 7th Edition”, David P. Rotella and Donald J. Abraham, eds., John Wiley and Sons, Hoboken, NY, 2009, in press.

Antineoplastic Polyamine Analogues, Mechanism-Based Inhibitors of Plasmepsin II, Inhibitors of Lysine-Specific Demethylase 1 as Potential Antitumor Agents, Bisguanidine and Biguanide Analogues as Antiparasitic and Antiinfective Agents

RO1-CA85509 Woster (PI)     3/01/00 – 2/28/06
NIH/NCI
Antineoplastic Polyamine Analogues
Synthesis and in vitro/in vivo evaluation of novel alkylpolyamine analogues as potential antitumor agents.
Role: Principal Investigator

Mechanism-Based Inhibitors of Plasmepsin II

National Institutes of Health 1R21AI076763. Title of proposal: Irreversible Inhibitors of Plasmepsin II
    Principal Investigator:     Patrick M. Woster, Ph.D. (15% effort)
    Funding period:         August 1, 2007 to July 31, 2009

Inhibitors of Lysine Specific Demethylase 1 as Antitumor Agents

Cellgate, Inc. Research Award. Title of proposal: Lysine-Specific Demethylase 1 Inhibitors.
    Principal Investigator:     Patrick M. Woster, Ph.D.
    Funding period:        May 1, 2007 through April 30, 2008